Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | ACP1 | P24666 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.55 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.55 |
| ▸ | HSPA9 | P38646 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21833960 | 0.86 | NPC1 (0.52) | TSHRNPC1RAB9ALMNAACP1 | |
| SCHEMBL20577108 | 0.83 | TSHR (0.57) | TSHRNPC1RAB9ALMNAACP1 | |
| SCHEMBL29700242 | 0.83 | TSHR (0.57) | TSHRNPC1RAB9ALMNAACP1 | |
| SCHEMBL20576592 | 0.81 | MEN1 (0.56) | TSHRNPC1RAB9ALMNAACP1 | |
| SCHEMBL21237720 | 0.80 | NPC1 (0.67) | TSHRNPC1RAB9ALMNAACP1 | |
| SCHEMBL20887927 | 0.80 | LMNA (0.75) | TSHRNPC1RAB9ALMNAACP1 | |
| SCHEMBL28858268 | 0.80 | LMNA (0.56) | TSHRNPC1RAB9ALMNAACP1 | |
| SCHEMBL28858269 | 0.80 | CYP1A2 (0.57) | TSHRNPC1RAB9ALMNAACP1 | |
| SCHEMBL4238173 | 0.79 | NPC1 (0.65) | TSHRNPC1RAB9ALMNAACP1 | |
| Hydrochloric Acid SCHEMBL20576283 | 0.79 | NPC1 (0.65) | TSHRNPC1RAB9ALMNAACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986407-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11117890-B2 | Substituted isoindole allosteric EGFR inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020257632-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3749664-A1 | COMPOUNDS WHICH CAUSE DEGRADATION OF EGFR, FOR USE AGAINST CANCER | F. Hoffmann-La Roche AG (CH) | 2020-12-16 | — | — | EP | disclosed |
| US-20200361930-A1 | BIFUNCTIONAL MOLECULES THAT DEGRADE EGFR | HOFFMANN-LA ROCHE INC. (US) | 2020-11-19 | — | — | US | disclosed |
| EP-3630754-A1 | COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102299-A1 | COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-04-02 | — | — | US | disclosed |
| WO-2019149922-A1 | COMPOUNDS WHICH CAUSE DEGRADATION OF EGFR, FOR USE AGAINST CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2019-08-08 | — | — | WO | disclosed |
| WO-2018220149-A1 | COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361930-A1 | BIFUNCTIONAL MOLECULES THAT DEGRADE EGFR | EGFR, ERBB2, MDM2 | TSHR 2389/4885NPC1 3422/4885RAB9A 1495/4885 |
| US-11117890-B2 | Substituted isoindole allosteric EGFR inhibitors | EGFR, ERBB2, ERBB3 | TSHR 783/4885NPC1 3517/4885RAB9A 1272/4885 |
| US-20200102299-A1 | COMPOUNDS | EGFR, ERBB2, ERBB3 | TSHR 723/4885NPC1 2485/4885RAB9A 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.